Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CO - Global Cord Blood to acquire clinical-stage biotech Cellenkos and its products rights

CO - Global Cord Blood to acquire clinical-stage biotech Cellenkos and its products rights

Global Cord Blood Corporation
Global Cord Blood (NYSE:CO) stock has added 6.7% to $3.66 in Friday aftermarket trading after it said it will acquire clinical-stage biotech Cellenkos and the rights to make and sell all of its existing and future products worldwide. Products related to Cellenkos' existing collaboration with Incyte (INCY) will not be a part of the deal. At deal close, Global Cord Blood will issue about 125M new shares valued at $11/share and pay $664M in cash as total consideration. Cellenkos is a biotechnology R&D company that utilizes umbilical cord blood as the raw material to develop cell based therapeutic products. CO stock -18.1% YTD.

For further details see:

Global Cord Blood to acquire clinical-stage biotech Cellenkos and its products rights
Stock Information
Company Name: Global Cord Blood Corporation
Stock Symbol: CO
Market: NYSE
Menu
CO CO Quote CO Short CO News CO Articles CO Message Board
Get CO Alerts

News, Short Squeeze, Breakout and More Instantly...